Peregrine Capital Management LLC Supernus Pharmaceuticals, Inc. Transaction History
Peregrine Capital Management LLC
- $3.18 Billion
- Q4 2024
A detailed history of Peregrine Capital Management LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Peregrine Capital Management LLC holds 135,678 shares of SUPN stock, worth $4.26 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
135,678
Previous 199,652
32.04%
Holding current value
$4.26 Million
Previous $6.23 Million
21.19%
% of portfolio
0.15%
Previous 0.2%
Shares
4 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$326 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$193 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$152 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$90.3 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$82.5 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.68B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...